Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTCJ2X8)

• DTT Name: Hepatitis C virus Non-structural 5A (HCV NS5A) DTT Info
• Gene Name: HCV NS5A

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daclatasvir	DMSFK9V	Hepatitis C virus infection	1E51.1	Approved	[1]
Glecaprevir; pibrentasvir	DMF6Z5T	Hepatitis C virus infection	1E51.1	Approved	[2]

13 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABT-267	DMNQ869	Hepatitis C virus infection	1E51.1	Phase 3	[3]
MK-8742	DMK301H	Hepatitis C virus infection	1E51.1	Phase 3	[4]
Ravidasvir	DM1LFUN	Hepatitis C	1E51	Phase 2/3	[5]
ACH-3102	DM0RPY5	Hepatitis C virus infection	1E51.1	Phase 2	[6]
GS-5885	DMSL3DX	Hepatitis C virus infection	1E51.1	Phase 2	[7]
PPI-668	DM4EHVB	Hepatitis C virus infection	1E51.1	Phase 2	[6]
AZD-2836	DMT2FAP	Hepatitis C virus infection	1E51.1	Phase 1/2	[8]
AV4025	DME630T	Hepatitis C virus infection	1E51.1	Phase 1	[9]
AZD-7295	DM84WXZ	Hepatitis C virus infection	1E51.1	Phase 1	[8]
BMS-824383	DMPQ5XC	Hepatitis C virus infection	1E51.1	Phase 1	[1]
EDP-239	DMXW07J	Hepatitis C virus infection	1E51.1	Phase 1	[6]
MB-110	DMPE0KD	Hepatitis C virus infection	1E51.1	Phase 1	[10]
PPI-461	DMTOXLG	Hepatitis C virus infection	1E51.1	Phase 1	[6]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACH-2928	DMSPW3N	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[11]

References

• [1] 2011 Pipeline of Bristol-Myers Squibb.
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57.
• [4] Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40.
• [5] Clinical pipeline report, company report or official report of Presidio Pharmaceuticals.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46.
• [8] TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.
• [9] Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem. 2014 Sep 25;57(18):7716-30.
• [10] Clinical pipeline report, company report or official report of Microbio.
• [11] Company report (Achillion)